Kavita ici final master 1226 with diabetes
2025-12-29
read master
plot 1year
plot 2year
plot 3year
plot 4year
plot 5year
final_master_1year
final_master_2year
final_master_3year
# final_master_4year
# final_master_5year
1year
| Characteristic | N = 1,3481 |
|---|---|
| Age | 73 (66, 79) |
| Gender_Legal_Sex | |
| Female | 520 (39%) |
| Male | 828 (61%) |
| male | |
| 0 | 520 (39%) |
| 1 | 828 (61%) |
| Race | |
| Asian | 53 (3.9%) |
| Black | 83 (6.2%) |
| Other/Unknown | 73 (5.4%) |
| White | 1,139 (84%) |
| Ethnic_Group | |
| Hispanic | 1,268 (94%) |
| Non_hispanic | 80 (5.9%) |
| ckd_incidence_1year | |
| 0 | 1,299 (96%) |
| 1 | 49 (3.6%) |
| ckd_progression_1year | |
| 0 | 1,073 (80%) |
| 1 | 275 (20%) |
| eskd_composite_1year | |
| 0 | 1,339 (99%) |
| 1 | 9 (0.7%) |
| ckd_composite_1year | |
| 0 | 1,023 (76%) |
| 1 | 325 (24%) |
| ckd_stage_1year | |
| 1 | 424 (31%) |
| 2 | 543 (40%) |
| 3 | 342 (25%) |
| 4 | 35 (2.6%) |
| 5 | 4 (0.3%) |
| ckd_stage_baseline | |
| 1 | 462 (34%) |
| 2 | 552 (41%) |
| 3 | 308 (23%) |
| 4 | 24 (1.8%) |
| 5 | 2 (0.1%) |
| dm | |
| 1 | 1,348 (100%) |
| htn | |
| 0 | 149 (11%) |
| 1 | 1,199 (89%) |
| cad | |
| 0 | 777 (58%) |
| 1 | 571 (42%) |
| ace_arb | |
| 0 | 331 (25%) |
| 1 | 1,017 (75%) |
| diu | |
| 0 | 380 (28%) |
| 1 | 968 (72%) |
| ppi | |
| 0 | 259 (19%) |
| 1 | 1,089 (81%) |
| steroids | |
| 0 | 212 (16%) |
| 1 | 1,136 (84%) |
| smoking | |
| 0 | 510 (38%) |
| 1 | 838 (62%) |
| Bevacizumab | |
| 0 | 1,261 (94%) |
| 1 | 87 (6.5%) |
| Cisplatin | |
| 0 | 1,171 (87%) |
| 1 | 177 (13%) |
| Carboplatin | |
| 0 | 884 (66%) |
| 1 | 464 (34%) |
| Pemetrexed | |
| 0 | 1,159 (86%) |
| 1 | 189 (14%) |
| Gemcitabine | |
| 0 | 1,170 (87%) |
| 1 | 178 (13%) |
| Cetuximab | |
| 0 | 1,311 (97%) |
| 1 | 37 (2.7%) |
| Trastuzumab | |
| 0 | 1,315 (98%) |
| 1 | 33 (2.4%) |
| VEGF_TKI | |
| 0 | 1,172 (87%) |
| 1 | 176 (13%) |
| pre_CRE_180days | 0.94 (0.75, 1.17) |
| pre_HGB_180days | 12.10 (10.80, 13.40) |
| Unknown | 7 |
| pre_ALB_180days | 4.00 (3.80, 4.30) |
| Unknown | 13 |
| eGFR_CRE_baseline | 79 (60, 95) |
| 1 Median (Q1, Q3); n (%) | |
2year
| Characteristic | N = 8051 |
|---|---|
| Age | 73 (66, 79) |
| Gender_Legal_Sex | |
| Female | 316 (39%) |
| Male | 489 (61%) |
| male | |
| 0 | 316 (39%) |
| 1 | 489 (61%) |
| Race | |
| Asian | 28 (3.5%) |
| Black | 51 (6.3%) |
| Other/Unknown | 45 (5.6%) |
| White | 681 (85%) |
| Ethnic_Group | |
| Hispanic | 759 (94%) |
| Non_hispanic | 46 (5.7%) |
| ckd_incidence_2year | |
| 0 | 753 (94%) |
| 1 | 52 (6.5%) |
| ckd_progression_2year | |
| 0 | 623 (77%) |
| 1 | 182 (23%) |
| eskd_composite_2year | |
| 0 | 794 (99%) |
| 1 | 11 (1.4%) |
| ckd_composite_2year | |
| 0 | 569 (71%) |
| 1 | 236 (29%) |
| ckd_stage_1year | |
| 1 | 250 (31%) |
| 2 | 327 (41%) |
| 3 | 208 (26%) |
| 4 | 17 (2.1%) |
| 5 | 3 (0.4%) |
| ckd_stage_2year | |
| 1 | 240 (30%) |
| 2 | 334 (41%) |
| 3 | 201 (25%) |
| 4 | 25 (3.1%) |
| 5 | 5 (0.6%) |
| ckd_stage_baseline | |
| 1 | 273 (34%) |
| 2 | 336 (42%) |
| 3 | 180 (22%) |
| 4 | 14 (1.7%) |
| 5 | 2 (0.2%) |
| dm | |
| 1 | 805 (100%) |
| htn | |
| 0 | 86 (11%) |
| 1 | 719 (89%) |
| cad | |
| 0 | 480 (60%) |
| 1 | 325 (40%) |
| ace_arb | |
| 0 | 194 (24%) |
| 1 | 611 (76%) |
| diu | |
| 0 | 224 (28%) |
| 1 | 581 (72%) |
| ppi | |
| 0 | 151 (19%) |
| 1 | 654 (81%) |
| steroids | |
| 0 | 131 (16%) |
| 1 | 674 (84%) |
| smoking | |
| 0 | 306 (38%) |
| 1 | 499 (62%) |
| Bevacizumab | |
| 0 | 756 (94%) |
| 1 | 49 (6.1%) |
| Cisplatin | |
| 0 | 705 (88%) |
| 1 | 100 (12%) |
| Carboplatin | |
| 0 | 537 (67%) |
| 1 | 268 (33%) |
| Pemetrexed | |
| 0 | 693 (86%) |
| 1 | 112 (14%) |
| Gemcitabine | |
| 0 | 706 (88%) |
| 1 | 99 (12%) |
| Cetuximab | |
| 0 | 785 (98%) |
| 1 | 20 (2.5%) |
| Trastuzumab | |
| 0 | 786 (98%) |
| 1 | 19 (2.4%) |
| VEGF_TKI | |
| 0 | 699 (87%) |
| 1 | 106 (13%) |
| pre_CRE_180days | 0.95 (0.76, 1.17) |
| pre_HGB_180days | 12.40 (10.90, 13.60) |
| Unknown | 4 |
| pre_ALB_180days | 4.10 (3.80, 4.30) |
| Unknown | 8 |
| eGFR_CRE_baseline | 80 (61, 94) |
| 1 Median (Q1, Q3); n (%) | |
3year
| Characteristic | N = 4701 |
|---|---|
| Age | 73 (66, 80) |
| Gender_Legal_Sex | |
| Female | 187 (40%) |
| Male | 283 (60%) |
| male | |
| 0 | 187 (40%) |
| 1 | 283 (60%) |
| Race | |
| Asian | 17 (3.6%) |
| Black | 26 (5.5%) |
| Other/Unknown | 25 (5.3%) |
| White | 402 (86%) |
| Ethnic_Group | |
| Hispanic | 444 (94%) |
| Non_hispanic | 26 (5.5%) |
| ckd_incidence_3year | |
| 0 | 426 (91%) |
| 1 | 44 (9.4%) |
| ckd_progression_3year | |
| 0 | 366 (78%) |
| 1 | 104 (22%) |
| eskd_composite_3year | |
| 0 | 462 (98%) |
| 1 | 8 (1.7%) |
| ckd_composite_3year | |
| 0 | 319 (68%) |
| 1 | 151 (32%) |
| ckd_stage_1year | |
| 1 | 147 (31%) |
| 2 | 189 (40%) |
| 3 | 123 (26%) |
| 4 | 9 (1.9%) |
| 5 | 2 (0.4%) |
| ckd_stage_2year | |
| 1 | 144 (31%) |
| 2 | 196 (42%) |
| 3 | 118 (25%) |
| 4 | 11 (2.3%) |
| 5 | 1 (0.2%) |
| ckd_stage_3year | |
| 1 | 133 (28%) |
| 2 | 192 (41%) |
| 3 | 129 (27%) |
| 4 | 13 (2.8%) |
| 5 | 3 (0.6%) |
| ckd_stage_baseline | |
| 1 | 172 (37%) |
| 2 | 186 (40%) |
| 3 | 105 (22%) |
| 4 | 6 (1.3%) |
| 5 | 1 (0.2%) |
| dm | |
| 1 | 470 (100%) |
| htn | |
| 0 | 53 (11%) |
| 1 | 417 (89%) |
| cad | |
| 0 | 285 (61%) |
| 1 | 185 (39%) |
| ace_arb | |
| 0 | 107 (23%) |
| 1 | 363 (77%) |
| diu | |
| 0 | 134 (29%) |
| 1 | 336 (71%) |
| ppi | |
| 0 | 89 (19%) |
| 1 | 381 (81%) |
| steroids | |
| 0 | 75 (16%) |
| 1 | 395 (84%) |
| smoking | |
| 0 | 178 (38%) |
| 1 | 292 (62%) |
| Bevacizumab | |
| 0 | 446 (95%) |
| 1 | 24 (5.1%) |
| Cisplatin | |
| 0 | 415 (88%) |
| 1 | 55 (12%) |
| Carboplatin | |
| 0 | 322 (69%) |
| 1 | 148 (31%) |
| Pemetrexed | |
| 0 | 398 (85%) |
| 1 | 72 (15%) |
| Gemcitabine | |
| 0 | 415 (88%) |
| 1 | 55 (12%) |
| Cetuximab | |
| 0 | 457 (97%) |
| 1 | 13 (2.8%) |
| Trastuzumab | |
| 0 | 460 (98%) |
| 1 | 10 (2.1%) |
| VEGF_TKI | |
| 0 | 409 (87%) |
| 1 | 61 (13%) |
| pre_CRE_180days | 0.94 (0.76, 1.17) |
| pre_HGB_180days | 12.50 (11.10, 13.70) |
| Unknown | 3 |
| pre_ALB_180days | 4.10 (3.80, 4.30) |
| Unknown | 4 |
| eGFR_CRE_baseline | 81 (61, 96) |
| 1 Median (Q1, Q3); n (%) | |
4year
| Characteristic | N = 2971 |
|---|---|
| Age | 74 (67, 80) |
| Gender_Legal_Sex | |
| Female | 117 (39%) |
| Male | 180 (61%) |
| male | |
| 0 | 117 (39%) |
| 1 | 180 (61%) |
| Race | |
| Asian | 8 (2.7%) |
| Black | 12 (4.0%) |
| Other/Unknown | 18 (6.1%) |
| White | 259 (87%) |
| Ethnic_Group | |
| Hispanic | 277 (93%) |
| Non_hispanic | 20 (6.7%) |
| ckd_incidence_4year | |
| 0 | 269 (91%) |
| 1 | 28 (9.4%) |
| ckd_progression_4year | |
| 0 | 228 (77%) |
| 1 | 69 (23%) |
| eskd_composite_4year | |
| 0 | 292 (98%) |
| 1 | 5 (1.7%) |
| ckd_composite_4year | |
| 0 | 199 (67%) |
| 1 | 98 (33%) |
| ckd_stage_1year | |
| 1 | 91 (31%) |
| 2 | 120 (40%) |
| 3 | 77 (26%) |
| 4 | 8 (2.7%) |
| 5 | 1 (0.3%) |
| ckd_stage_2year | |
| 1 | 88 (30%) |
| 2 | 126 (42%) |
| 3 | 74 (25%) |
| 4 | 9 (3.0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 81 (27%) |
| 2 | 123 (41%) |
| 3 | 86 (29%) |
| 4 | 6 (2.0%) |
| 5 | 1 (0.3%) |
| ckd_stage_4year | |
| 1 | 86 (29%) |
| 2 | 119 (40%) |
| 3 | 86 (29%) |
| 4 | 5 (1.7%) |
| 5 | 1 (0.3%) |
| ckd_stage_baseline | |
| 1 | 102 (34%) |
| 2 | 121 (41%) |
| 3 | 70 (24%) |
| 4 | 4 (1.3%) |
| 5 | 0 (0%) |
| dm | |
| 1 | 297 (100%) |
| htn | |
| 0 | 36 (12%) |
| 1 | 261 (88%) |
| cad | |
| 0 | 176 (59%) |
| 1 | 121 (41%) |
| ace_arb | |
| 0 | 57 (19%) |
| 1 | 240 (81%) |
| diu | |
| 0 | 77 (26%) |
| 1 | 220 (74%) |
| ppi | |
| 0 | 60 (20%) |
| 1 | 237 (80%) |
| steroids | |
| 0 | 52 (18%) |
| 1 | 245 (82%) |
| smoking | |
| 0 | 113 (38%) |
| 1 | 184 (62%) |
| Bevacizumab | |
| 0 | 284 (96%) |
| 1 | 13 (4.4%) |
| Cisplatin | |
| 0 | 266 (90%) |
| 1 | 31 (10%) |
| Carboplatin | |
| 0 | 214 (72%) |
| 1 | 83 (28%) |
| Pemetrexed | |
| 0 | 251 (85%) |
| 1 | 46 (15%) |
| Gemcitabine | |
| 0 | 266 (90%) |
| 1 | 31 (10%) |
| Cetuximab | |
| 0 | 292 (98%) |
| 1 | 5 (1.7%) |
| Trastuzumab | |
| 0 | 290 (98%) |
| 1 | 7 (2.4%) |
| VEGF_TKI | |
| 0 | 259 (87%) |
| 1 | 38 (13%) |
| pre_CRE_180days | 0.96 (0.77, 1.19) |
| pre_HGB_180days | 12.60 (11.10, 13.90) |
| Unknown | 1 |
| pre_ALB_180days | 4.10 (3.80, 4.40) |
| Unknown | 1 |
| eGFR_CRE_baseline | 79 (61, 95) |
| 1 Median (Q1, Q3); n (%) | |
5year
| Characteristic | N = 1831 |
|---|---|
| Age | 75 (67, 82) |
| Gender_Legal_Sex | |
| Female | 74 (40%) |
| Male | 109 (60%) |
| male | |
| 0 | 74 (40%) |
| 1 | 109 (60%) |
| Race | |
| Asian | 4 (2.2%) |
| Black | 10 (5.5%) |
| Other/Unknown | 13 (7.1%) |
| White | 156 (85%) |
| Ethnic_Group | |
| Hispanic | 168 (92%) |
| Non_hispanic | 15 (8.2%) |
| ckd_incidence_5year | |
| 0 | 160 (87%) |
| 1 | 23 (13%) |
| ckd_progression_5year | |
| 0 | 145 (79%) |
| 1 | 38 (21%) |
| eskd_composite_5year | |
| 0 | 179 (98%) |
| 1 | 4 (2.2%) |
| ckd_composite_5year | |
| 0 | 121 (66%) |
| 1 | 62 (34%) |
| ckd_stage_1year | |
| 1 | 54 (30%) |
| 2 | 77 (42%) |
| 3 | 48 (26%) |
| 4 | 3 (1.6%) |
| 5 | 1 (0.5%) |
| ckd_stage_2year | |
| 1 | 51 (28%) |
| 2 | 83 (45%) |
| 3 | 44 (24%) |
| 4 | 5 (2.7%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 47 (26%) |
| 2 | 86 (47%) |
| 3 | 47 (26%) |
| 4 | 2 (1.1%) |
| 5 | 1 (0.5%) |
| ckd_stage_4year | |
| 1 | 50 (27%) |
| 2 | 81 (44%) |
| 3 | 49 (27%) |
| 4 | 2 (1.1%) |
| 5 | 1 (0.5%) |
| ckd_stage_5year | |
| 1 | 44 (24%) |
| 2 | 89 (49%) |
| 3 | 43 (23%) |
| 4 | 6 (3.3%) |
| 5 | 1 (0.5%) |
| ckd_stage_baseline | |
| 1 | 63 (34%) |
| 2 | 78 (43%) |
| 3 | 39 (21%) |
| 4 | 3 (1.6%) |
| 5 | 0 (0%) |
| dm | |
| 1 | 183 (100%) |
| htn | |
| 0 | 20 (11%) |
| 1 | 163 (89%) |
| cad | |
| 0 | 113 (62%) |
| 1 | 70 (38%) |
| ace_arb | |
| 0 | 35 (19%) |
| 1 | 148 (81%) |
| diu | |
| 0 | 44 (24%) |
| 1 | 139 (76%) |
| ppi | |
| 0 | 37 (20%) |
| 1 | 146 (80%) |
| steroids | |
| 0 | 35 (19%) |
| 1 | 148 (81%) |
| smoking | |
| 0 | 70 (38%) |
| 1 | 113 (62%) |
| Bevacizumab | |
| 0 | 175 (96%) |
| 1 | 8 (4.4%) |
| Cisplatin | |
| 0 | 164 (90%) |
| 1 | 19 (10%) |
| Carboplatin | |
| 0 | 131 (72%) |
| 1 | 52 (28%) |
| Pemetrexed | |
| 0 | 161 (88%) |
| 1 | 22 (12%) |
| Gemcitabine | |
| 0 | 163 (89%) |
| 1 | 20 (11%) |
| Cetuximab | |
| 0 | 181 (99%) |
| 1 | 2 (1.1%) |
| Trastuzumab | |
| 0 | 181 (99%) |
| 1 | 2 (1.1%) |
| VEGF_TKI | |
| 0 | 164 (90%) |
| 1 | 19 (10%) |
| pre_CRE_180days | 0.95 (0.75, 1.16) |
| pre_HGB_180days | 12.60 (11.20, 13.80) |
| Unknown | 1 |
| pre_ALB_180days | 4.10 (3.80, 4.30) |
| Unknown | 1 |
| eGFR_CRE_baseline | 79 (61, 96) |
| 1 Median (Q1, Q3); n (%) | |
6year
| Characteristic | N = 1161 |
|---|---|
| Age | 73 (66, 82) |
| Gender_Legal_Sex | |
| Female | 48 (41%) |
| Male | 68 (59%) |
| male | |
| 0 | 48 (41%) |
| 1 | 68 (59%) |
| Race | |
| Asian | 2 (1.7%) |
| Black | 9 (7.8%) |
| Other/Unknown | 11 (9.5%) |
| White | 94 (81%) |
| Ethnic_Group | |
| Hispanic | 104 (90%) |
| Non_hispanic | 12 (10%) |
| ckd_incidence_6year | |
| 0 | 99 (85%) |
| 1 | 17 (15%) |
| ckd_progression_6year | |
| 0 | 92 (79%) |
| 1 | 24 (21%) |
| eskd_composite_6year | |
| 0 | 114 (98%) |
| 1 | 2 (1.7%) |
| ckd_composite_6year | |
| 0 | 74 (64%) |
| 1 | 42 (36%) |
| ckd_stage_1year | |
| 1 | 38 (33%) |
| 2 | 50 (43%) |
| 3 | 27 (23%) |
| 4 | 1 (0.9%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 35 (30%) |
| 2 | 54 (47%) |
| 3 | 27 (23%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 35 (30%) |
| 2 | 50 (43%) |
| 3 | 30 (26%) |
| 4 | 1 (0.9%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 36 (31%) |
| 2 | 50 (43%) |
| 3 | 30 (26%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 31 (27%) |
| 2 | 57 (49%) |
| 3 | 26 (22%) |
| 4 | 2 (1.7%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 31 (27%) |
| 2 | 56 (48%) |
| 3 | 23 (20%) |
| 4 | 6 (5.2%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 43 (37%) |
| 2 | 47 (41%) |
| 3 | 25 (22%) |
| 4 | 1 (0.9%) |
| 5 | 0 (0%) |
| dm | |
| 1 | 116 (100%) |
| htn | |
| 0 | 14 (12%) |
| 1 | 102 (88%) |
| cad | |
| 0 | 76 (66%) |
| 1 | 40 (34%) |
| ace_arb | |
| 0 | 24 (21%) |
| 1 | 92 (79%) |
| diu | |
| 0 | 30 (26%) |
| 1 | 86 (74%) |
| ppi | |
| 0 | 24 (21%) |
| 1 | 92 (79%) |
| steroids | |
| 0 | 23 (20%) |
| 1 | 93 (80%) |
| smoking | |
| 0 | 50 (43%) |
| 1 | 66 (57%) |
| Bevacizumab | |
| 0 | 112 (97%) |
| 1 | 4 (3.4%) |
| Cisplatin | |
| 0 | 104 (90%) |
| 1 | 12 (10%) |
| Carboplatin | |
| 0 | 85 (73%) |
| 1 | 31 (27%) |
| Pemetrexed | |
| 0 | 101 (87%) |
| 1 | 15 (13%) |
| Gemcitabine | |
| 0 | 106 (91%) |
| 1 | 10 (8.6%) |
| Cetuximab | |
| 0 | 115 (99%) |
| 1 | 1 (0.9%) |
| Trastuzumab | |
| 0 | 115 (99%) |
| 1 | 1 (0.9%) |
| VEGF_TKI | |
| 0 | 107 (92%) |
| 1 | 9 (7.8%) |
| pre_CRE_180days | 0.93 (0.73, 1.13) |
| pre_HGB_180days | 12.60 (11.10, 13.90) |
| pre_ALB_180days | 4.10 (3.80, 4.30) |
| eGFR_CRE_baseline | 82 (65, 98) |
| 1 Median (Q1, Q3); n (%) | |
7year
| Characteristic | N = 791 |
|---|---|
| Age | 72 (65, 82) |
| Gender_Legal_Sex | |
| Female | 29 (37%) |
| Male | 50 (63%) |
| male | |
| 0 | 29 (37%) |
| 1 | 50 (63%) |
| Race | |
| Asian | 1 (1.3%) |
| Black | 6 (7.6%) |
| Other/Unknown | 8 (10%) |
| White | 64 (81%) |
| Ethnic_Group | |
| Hispanic | 70 (89%) |
| Non_hispanic | 9 (11%) |
| ckd_incidence_7year | |
| 0 | 63 (80%) |
| 1 | 16 (20%) |
| ckd_progression_7year | |
| 0 | 63 (80%) |
| 1 | 16 (20%) |
| eskd_composite_7year | |
| 0 | 78 (99%) |
| 1 | 1 (1.3%) |
| ckd_composite_7year | |
| 0 | 47 (59%) |
| 1 | 32 (41%) |
| ckd_stage_1year | |
| 1 | 28 (35%) |
| 2 | 33 (42%) |
| 3 | 17 (22%) |
| 4 | 1 (1.3%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 25 (32%) |
| 2 | 35 (44%) |
| 3 | 19 (24%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 25 (32%) |
| 2 | 35 (44%) |
| 3 | 19 (24%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 26 (33%) |
| 2 | 31 (39%) |
| 3 | 22 (28%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 20 (25%) |
| 2 | 40 (51%) |
| 3 | 18 (23%) |
| 4 | 1 (1.3%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 20 (25%) |
| 2 | 38 (48%) |
| 3 | 17 (22%) |
| 4 | 4 (5.1%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 21 (27%) |
| 2 | 33 (42%) |
| 3 | 21 (27%) |
| 4 | 3 (3.8%) |
| 5 | 1 (1.3%) |
| ckd_stage_baseline | |
| 1 | 31 (39%) |
| 2 | 30 (38%) |
| 3 | 17 (22%) |
| 4 | 1 (1.3%) |
| 5 | 0 (0%) |
| dm | |
| 1 | 79 (100%) |
| htn | |
| 0 | 10 (13%) |
| 1 | 69 (87%) |
| cad | |
| 0 | 55 (70%) |
| 1 | 24 (30%) |
| ace_arb | |
| 0 | 15 (19%) |
| 1 | 64 (81%) |
| diu | |
| 0 | 24 (30%) |
| 1 | 55 (70%) |
| ppi | |
| 0 | 16 (20%) |
| 1 | 63 (80%) |
| steroids | |
| 0 | 16 (20%) |
| 1 | 63 (80%) |
| smoking | |
| 0 | 31 (39%) |
| 1 | 48 (61%) |
| Bevacizumab | |
| 0 | 75 (95%) |
| 1 | 4 (5.1%) |
| Cisplatin | |
| 0 | 73 (92%) |
| 1 | 6 (7.6%) |
| Carboplatin | |
| 0 | 58 (73%) |
| 1 | 21 (27%) |
| Pemetrexed | |
| 0 | 69 (87%) |
| 1 | 10 (13%) |
| Gemcitabine | |
| 0 | 72 (91%) |
| 1 | 7 (8.9%) |
| Cetuximab | |
| 0 | 79 (100%) |
| Trastuzumab | |
| 0 | 78 (99%) |
| 1 | 1 (1.3%) |
| VEGF_TKI | |
| 0 | 72 (91%) |
| 1 | 7 (8.9%) |
| pre_CRE_180days | 0.95 (0.73, 1.13) |
| pre_HGB_180days | 12.60 (11.10, 13.90) |
| pre_ALB_180days | 4.10 (3.90, 4.30) |
| eGFR_CRE_baseline | 82 (63, 98) |
| 1 Median (Q1, Q3); n (%) | |
8year
| Characteristic | N = 411 |
|---|---|
| Age | 76 (67, 83) |
| Gender_Legal_Sex | |
| Female | 12 (29%) |
| Male | 29 (71%) |
| male | |
| 0 | 12 (29%) |
| 1 | 29 (71%) |
| Race | |
| Asian | 0 (0%) |
| Black | 3 (7.3%) |
| Other/Unknown | 3 (7.3%) |
| White | 35 (85%) |
| Ethnic_Group | |
| Hispanic | 35 (85%) |
| Non_hispanic | 6 (15%) |
| ckd_incidence_8year | |
| 0 | 28 (68%) |
| 1 | 13 (32%) |
| ckd_progression_8year | |
| 0 | 31 (76%) |
| 1 | 10 (24%) |
| eskd_composite_8year | |
| 0 | 41 (100%) |
| ckd_composite_8year | |
| 0 | 18 (44%) |
| 1 | 23 (56%) |
| ckd_stage_1year | |
| 1 | 13 (32%) |
| 2 | 18 (44%) |
| 3 | 10 (24%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 9 (22%) |
| 2 | 21 (51%) |
| 3 | 11 (27%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 11 (27%) |
| 2 | 19 (46%) |
| 3 | 11 (27%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 13 (32%) |
| 2 | 14 (34%) |
| 3 | 14 (34%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 9 (22%) |
| 2 | 19 (46%) |
| 3 | 13 (32%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 8 (20%) |
| 2 | 20 (49%) |
| 3 | 12 (29%) |
| 4 | 1 (2.4%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 9 (22%) |
| 2 | 14 (34%) |
| 3 | 16 (39%) |
| 4 | 2 (4.9%) |
| 5 | 0 (0%) |
| ckd_stage_8year | |
| 1 | 8 (20%) |
| 2 | 14 (34%) |
| 3 | 17 (41%) |
| 4 | 2 (4.9%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 12 (29%) |
| 2 | 17 (41%) |
| 3 | 12 (29%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| dm | |
| 1 | 41 (100%) |
| htn | |
| 0 | 2 (4.9%) |
| 1 | 39 (95%) |
| cad | |
| 0 | 26 (63%) |
| 1 | 15 (37%) |
| ace_arb | |
| 0 | 8 (20%) |
| 1 | 33 (80%) |
| diu | |
| 0 | 11 (27%) |
| 1 | 30 (73%) |
| ppi | |
| 0 | 10 (24%) |
| 1 | 31 (76%) |
| steroids | |
| 0 | 11 (27%) |
| 1 | 30 (73%) |
| smoking | |
| 0 | 16 (39%) |
| 1 | 25 (61%) |
| Bevacizumab | |
| 0 | 39 (95%) |
| 1 | 2 (4.9%) |
| Cisplatin | |
| 0 | 39 (95%) |
| 1 | 2 (4.9%) |
| Carboplatin | |
| 0 | 33 (80%) |
| 1 | 8 (20%) |
| Pemetrexed | |
| 0 | 37 (90%) |
| 1 | 4 (9.8%) |
| Gemcitabine | |
| 0 | 38 (93%) |
| 1 | 3 (7.3%) |
| Cetuximab | |
| 0 | 41 (100%) |
| Trastuzumab | |
| 0 | 40 (98%) |
| 1 | 1 (2.4%) |
| VEGF_TKI | |
| 0 | 39 (95%) |
| 1 | 2 (4.9%) |
| pre_CRE_180days | 1.02 (0.78, 1.21) |
| pre_HGB_180days | 12.50 (11.10, 13.90) |
| pre_ALB_180days | 4.10 (3.90, 4.30) |
| eGFR_CRE_baseline | 77 (59, 93) |
| 1 Median (Q1, Q3); n (%) | |
9year
| Characteristic | N = 191 |
|---|---|
| Age | 78 (65, 84) |
| Gender_Legal_Sex | |
| Female | 6 (32%) |
| Male | 13 (68%) |
| male | |
| 0 | 6 (32%) |
| 1 | 13 (68%) |
| Race | |
| Asian | 0 (0%) |
| Black | 0 (0%) |
| Other/Unknown | 1 (5.3%) |
| White | 18 (95%) |
| Ethnic_Group | |
| Hispanic | 17 (89%) |
| Non_hispanic | 2 (11%) |
| ckd_incidence_9year | |
| 0 | 14 (74%) |
| 1 | 5 (26%) |
| ckd_progression_9year | |
| 0 | 15 (79%) |
| 1 | 4 (21%) |
| eskd_composite_9year | |
| 0 | 19 (100%) |
| ckd_composite_9year | |
| 0 | 10 (53%) |
| 1 | 9 (47%) |
| ckd_stage_1year | |
| 1 | 5 (26%) |
| 2 | 10 (53%) |
| 3 | 4 (21%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 4 (21%) |
| 2 | 10 (53%) |
| 3 | 5 (26%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 5 (26%) |
| 2 | 9 (47%) |
| 3 | 5 (26%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 8 (42%) |
| 2 | 5 (26%) |
| 3 | 6 (32%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 5 (26%) |
| 2 | 8 (42%) |
| 3 | 6 (32%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 5 (26%) |
| 2 | 7 (37%) |
| 3 | 7 (37%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 7 (37%) |
| 2 | 5 (26%) |
| 3 | 7 (37%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_8year | |
| 1 | 6 (32%) |
| 2 | 6 (32%) |
| 3 | 6 (32%) |
| 4 | 1 (5.3%) |
| 5 | 0 (0%) |
| ckd_stage_9year | |
| 1 | 8 (42%) |
| 2 | 3 (16%) |
| 3 | 8 (42%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 5 (26%) |
| 2 | 9 (47%) |
| 3 | 5 (26%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| dm | |
| 1 | 19 (100%) |
| htn | |
| 0 | 0 (0%) |
| 1 | 19 (100%) |
| cad | |
| 0 | 13 (68%) |
| 1 | 6 (32%) |
| ace_arb | |
| 0 | 5 (26%) |
| 1 | 14 (74%) |
| diu | |
| 0 | 5 (26%) |
| 1 | 14 (74%) |
| ppi | |
| 0 | 4 (21%) |
| 1 | 15 (79%) |
| steroids | |
| 0 | 4 (21%) |
| 1 | 15 (79%) |
| smoking | |
| 0 | 7 (37%) |
| 1 | 12 (63%) |
| Bevacizumab | |
| 0 | 18 (95%) |
| 1 | 1 (5.3%) |
| Cisplatin | |
| 0 | 18 (95%) |
| 1 | 1 (5.3%) |
| Carboplatin | |
| 0 | 14 (74%) |
| 1 | 5 (26%) |
| Pemetrexed | |
| 0 | 16 (84%) |
| 1 | 3 (16%) |
| Gemcitabine | |
| 0 | 19 (100%) |
| Cetuximab | |
| 0 | 19 (100%) |
| Trastuzumab | |
| 0 | 18 (95%) |
| 1 | 1 (5.3%) |
| VEGF_TKI | |
| 0 | 18 (95%) |
| 1 | 1 (5.3%) |
| pre_CRE_180days | 1.02 (0.83, 1.15) |
| pre_HGB_180days | 12.60 (11.70, 14.40) |
| pre_ALB_180days | |
| 3.5 | 1 (5.3%) |
| 3.9 | 1 (5.3%) |
| 4 | 2 (11%) |
| 4.1 | 2 (11%) |
| 4.2 | 6 (32%) |
| 4.3 | 4 (21%) |
| 4.4 | 2 (11%) |
| 4.8 | 1 (5.3%) |
| eGFR_CRE_baseline | 77 (59, 92) |
| 1 Median (Q1, Q3); n (%) | |
10year
| Characteristic | N = 71 |
|---|---|
| Age | |
| 73 | 1 (14%) |
| 78 | 1 (14%) |
| 82 | 1 (14%) |
| 83 | 1 (14%) |
| 87 | 2 (29%) |
| 99 | 1 (14%) |
| Gender_Legal_Sex | |
| Female | 2 (29%) |
| Male | 5 (71%) |
| male | |
| 0 | 2 (29%) |
| 1 | 5 (71%) |
| Race | |
| Asian | 0 (0%) |
| Black | 0 (0%) |
| Other/Unknown | 1 (14%) |
| White | 6 (86%) |
| Ethnic_Group | |
| Hispanic | 6 (86%) |
| Non_hispanic | 1 (14%) |
| ckd_incidence_10year | |
| 0 | 4 (57%) |
| 1 | 3 (43%) |
| ckd_progression_10year | |
| 0 | 4 (57%) |
| 1 | 3 (43%) |
| eskd_composite_10year | |
| 0 | 6 (86%) |
| 1 | 1 (14%) |
| ckd_composite_10year | |
| 0 | 1 (14%) |
| 1 | 6 (86%) |
| ckd_stage_1year | |
| 1 | 1 (14%) |
| 2 | 3 (43%) |
| 3 | 3 (43%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_2year | |
| 1 | 1 (14%) |
| 2 | 2 (29%) |
| 3 | 4 (57%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_3year | |
| 1 | 1 (14%) |
| 2 | 2 (29%) |
| 3 | 4 (57%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_4year | |
| 1 | 1 (14%) |
| 2 | 2 (29%) |
| 3 | 4 (57%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_5year | |
| 1 | 1 (14%) |
| 2 | 2 (29%) |
| 3 | 4 (57%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_6year | |
| 1 | 1 (14%) |
| 2 | 2 (29%) |
| 3 | 4 (57%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_7year | |
| 1 | 0 (0%) |
| 2 | 2 (29%) |
| 3 | 5 (71%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_8year | |
| 1 | 1 (14%) |
| 2 | 1 (14%) |
| 3 | 4 (57%) |
| 4 | 1 (14%) |
| 5 | 0 (0%) |
| ckd_stage_9year | |
| 1 | 1 (14%) |
| 2 | 0 (0%) |
| 3 | 6 (86%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| ckd_stage_10year | |
| 1 | 0 (0%) |
| 2 | 1 (14%) |
| 3 | 4 (57%) |
| 4 | 2 (29%) |
| 5 | 0 (0%) |
| ckd_stage_baseline | |
| 1 | 1 (14%) |
| 2 | 3 (43%) |
| 3 | 3 (43%) |
| 4 | 0 (0%) |
| 5 | 0 (0%) |
| dm | |
| 1 | 7 (100%) |
| htn | |
| 0 | 0 (0%) |
| 1 | 7 (100%) |
| cad | |
| 0 | 4 (57%) |
| 1 | 3 (43%) |
| ace_arb | |
| 0 | 0 (0%) |
| 1 | 7 (100%) |
| diu | |
| 0 | 1 (14%) |
| 1 | 6 (86%) |
| ppi | |
| 0 | 1 (14%) |
| 1 | 6 (86%) |
| steroids | |
| 0 | 2 (29%) |
| 1 | 5 (71%) |
| smoking | |
| 0 | 1 (14%) |
| 1 | 6 (86%) |
| Bevacizumab | |
| 0 | 7 (100%) |
| Cisplatin | |
| 0 | 6 (86%) |
| 1 | 1 (14%) |
| Carboplatin | |
| 0 | 6 (86%) |
| 1 | 1 (14%) |
| Pemetrexed | |
| 0 | 6 (86%) |
| 1 | 1 (14%) |
| Gemcitabine | |
| 0 | 7 (100%) |
| Cetuximab | |
| 0 | 7 (100%) |
| Trastuzumab | |
| 0 | 6 (86%) |
| 1 | 1 (14%) |
| VEGF_TKI | |
| 0 | 7 (100%) |
| pre_CRE_180days | |
| 0.66 | 1 (14%) |
| 0.81 | 1 (14%) |
| 1.01 | 1 (14%) |
| 1.02 | 1 (14%) |
| 1.15 | 1 (14%) |
| 1.3 | 1 (14%) |
| 1.52 | 1 (14%) |
| pre_HGB_180days | |
| 11.3 | 1 (14%) |
| 12 | 1 (14%) |
| 12.2 | 1 (14%) |
| 13.3 | 1 (14%) |
| 13.9 | 1 (14%) |
| 14.6 | 1 (14%) |
| 14.8 | 1 (14%) |
| pre_ALB_180days | |
| 4.1 | 1 (14%) |
| 4.2 | 2 (29%) |
| 4.3 | 2 (29%) |
| 4.4 | 1 (14%) |
| 4.8 | 1 (14%) |
| eGFR_CRE_baseline | |
| 47.0718538399253 | 1 (14%) |
| 55.042438335428 | 1 (14%) |
| 59.186554146736 | 1 (14%) |
| 61.3166133202947 | 1 (14%) |
| 80.4651484382125 | 1 (14%) |
| 82.827699890859 | 1 (14%) |
| 104.256040676399 | 1 (14%) |
| 1 n (%) | |
landmark 1year
landmark 2year
landmark 3year
landmark 4year
landmark 5year
# ckd_stage vs ckd_composite_5year
| 0 (N=121) |
1 (N=62) |
Overall (N=183) |
|
|---|---|---|---|
| ckd_stage_baseline_3 | |||
| stage 1 | 58 (47.9%) | 5 (8.1%) | 63 (34.4%) |
| stage 2 | 57 (47.1%) | 21 (33.9%) | 78 (42.6%) |
| stage 3 or more | 6 (5.0%) | 36 (58.1%) | 42 (23.0%) |
| ckd_stage_5year_3 | |||
| stage 1 | 42 (34.7%) | 2 (3.2%) | 44 (24.0%) |
| stage 2 | 74 (61.2%) | 15 (24.2%) | 89 (48.6%) |
| stage 3 or more | 5 (4.1%) | 45 (72.6%) | 50 (27.3%) |
ckd_stage vs ckd_composite_5year
| 0 (N=121) |
1 (N=62) |
Overall (N=183) |
|
|---|---|---|---|
| ckd_stage_baseline_3 | |||
| stage 1 | 58 (47.9%) | 5 (8.1%) | 63 (34.4%) |
| stage 2 | 57 (47.1%) | 21 (33.9%) | 78 (42.6%) |
| stage 3 or more | 6 (5.0%) | 36 (58.1%) | 42 (23.0%) |
| ckd_stage_5year_3 | |||
| stage 1 | 42 (34.7%) | 2 (3.2%) | 44 (24.0%) |
| stage 2 | 74 (61.2%) | 15 (24.2%) | 89 (48.6%) |
| stage 3 or more | 5 (4.1%) | 45 (72.6%) | 50 (27.3%) |
ckd_stage vs ckd_composite_5year
| 0 (N=121) |
1 (N=62) |
Overall (N=183) |
|
|---|---|---|---|
| ckd_stage_baseline_3 | |||
| stage 1 | 58 (47.9%) | 5 (8.1%) | 63 (34.4%) |
| stage 2 | 57 (47.1%) | 21 (33.9%) | 78 (42.6%) |
| stage 3 or more | 6 (5.0%) | 36 (58.1%) | 42 (23.0%) |
| ckd_stage_5year_3 | |||
| stage 1 | 42 (34.7%) | 2 (3.2%) | 44 (24.0%) |
| stage 2 | 74 (61.2%) | 15 (24.2%) | 89 (48.6%) |
| stage 3 or more | 5 (4.1%) | 45 (72.6%) | 50 (27.3%) |
ckd_stage vs ckd_composite_5year
| 0 (N=121) |
1 (N=62) |
Overall (N=183) |
|
|---|---|---|---|
| ckd_stage_baseline_3 | |||
| stage 1 | 58 (47.9%) | 5 (8.1%) | 63 (34.4%) |
| stage 2 | 57 (47.1%) | 21 (33.9%) | 78 (42.6%) |
| stage 3 or more | 6 (5.0%) | 36 (58.1%) | 42 (23.0%) |
| ckd_stage_5year_3 | |||
| stage 1 | 42 (34.7%) | 2 (3.2%) | 44 (24.0%) |
| stage 2 | 74 (61.2%) | 15 (24.2%) | 89 (48.6%) |
| stage 3 or more | 5 (4.1%) | 45 (72.6%) | 50 (27.3%) |
ckd_stage vs ckd_composite_5year
| 0 (N=121) |
1 (N=62) |
Overall (N=183) |
|
|---|---|---|---|
| ckd_stage_baseline_3 | |||
| stage 1 | 58 (47.9%) | 5 (8.1%) | 63 (34.4%) |
| stage 2 | 57 (47.1%) | 21 (33.9%) | 78 (42.6%) |
| stage 3 or more | 6 (5.0%) | 36 (58.1%) | 42 (23.0%) |
| ckd_stage_5year_3 | |||
| stage 1 | 42 (34.7%) | 2 (3.2%) | 44 (24.0%) |
| stage 2 | 74 (61.2%) | 15 (24.2%) | 89 (48.6%) |
| stage 3 or more | 5 (4.1%) | 45 (72.6%) | 50 (27.3%) |
logistic regression outcome: ckd_composite_5year
| Characteristic | N | OR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| year_10 | 183 | 1.68 | 1.21, 2.40 | 0.003 |
| Gender_Legal_Sex | 183 | |||
| Female | — | — | ||
| Male | 1.12 | 0.60, 2.10 | 0.733 | |
| male | 183 | |||
| 0 | — | — | ||
| 1 | 1.12 | 0.60, 2.10 | 0.733 | |
| Race | 183 | |||
| Asian | — | — | ||
| Black | 36,519,843 | 0.00, |
0.988 | |
| Other/Unknown | 9,782,101 | 0.00, |
0.989 | |
| White | 7,382,718 | 0.00, |
0.989 | |
| htn | 183 | |||
| 0 | — | — | ||
| 1 | 1.61 | 0.59, 5.16 | 0.377 | |
| cad | 183 | |||
| 0 | — | — | ||
| 1 | 2.58 | 1.38, 4.89 | 0.003 | |
| ace_arb | 183 | |||
| 0 | — | — | ||
| 1 | 1.94 | 0.85, 4.84 | 0.130 | |
| diu | 183 | |||
| 0 | — | — | ||
| 1 | 3.46 | 1.52, 8.97 | 0.005 | |
| ppi | 183 | |||
| 0 | — | — | ||
| 1 | 1.77 | 0.80, 4.24 | 0.173 | |
| steroids | 183 | |||
| 0 | — | — | ||
| 1 | 0.46 | 0.22, 0.98 | 0.044 | |
| smoking | 183 | |||
| 0 | — | — | ||
| 1 | 1.08 | 0.57, 2.04 | 0.818 | |
| statins | 183 | 1.63 | 0.64, 4.71 | 0.328 |
| Bevacizumab | 183 | |||
| 0 | — | — | ||
| 1 | 3.45 | 0.82, 17.3 | 0.098 | |
| Cisplatin | 183 | |||
| 0 | — | — | ||
| 1 | 0.67 | 0.21, 1.85 | 0.464 | |
| Carboplatin | 183 | |||
| 0 | — | — | ||
| 1 | 0.64 | 0.31, 1.27 | 0.212 | |
| Pemetrexed | 183 | |||
| 0 | — | — | ||
| 1 | 0.90 | 0.33, 2.27 | 0.828 | |
| Gemcitabine | 183 | |||
| 0 | — | — | ||
| 1 | 2.68 | 1.05, 7.05 | 0.040 | |
| Cetuximab | 183 | |||
| 0 | — | — | ||
| 1 | 1.97 | 0.08, 50.3 | 0.634 | |
| Trastuzumab | 183 | |||
| 0 | — | — | ||
| 1 | 1.97 | 0.08, 50.3 | 0.634 | |
| VEGF_TKI | 183 | |||
| 0 | — | — | ||
| 1 | 3.91 | 1.48, 11.1 | 0.007 | |
| eGFR_CRE_5year_decrease_10 | 183 | 3.44 | 2.48, 5.20 | <0.001 |
| ICI_Class | 183 | |||
| PD1 | — | — | ||
| Combination | 1.11 | 0.32, 3.42 | 0.858 | |
| CTLA4 | 1.00 | 0.20, 3.99 | >0.999 | |
| PDL1 | 1.10 | 0.47, 2.47 | 0.820 | |
| cancer_type | 183 | |||
| Breast | — | — | ||
| Cutaneous / Melanoma | 1.13 | 0.13, 23.7 | 0.921 | |
| GI | 5.00 | 0.41, 131 | 0.239 | |
| GU | 4.00 | 0.46, 85.4 | 0.250 | |
| gyn | 0.00 | 0.995 | ||
| GYN | 3.00 | 0.21, 83.0 | 0.437 | |
| Head and Neck | 1.33 | 0.12, 31.7 | 0.825 | |
| Heme | 1.88 | 0.18, 44.0 | 0.625 | |
| Neuro | 0.00 | 0.00, 43,378,369,159,442,186,240 | 0.993 | |
| Sarcoma | 0.00 | 0.00, 12,768,779,613,888,755,712 | 0.993 | |
| thoracic | 0.00 | 0.995 | ||
| Thoracic | 0.79 | 0.09, 17.1 | 0.849 | |
| pre_CRE_180days | 183 | 56.9 | 15.7, 252 | <0.001 |
| 1 OR = Odds Ratio, CI = Confidence Interval | ||||
cox model outcome: death
| Characteristic | N | HR1 | 95% CI1 | p-value |
|---|---|---|---|---|
| year_10 | 183 | 0.94 | 0.82, 1.07 | 0.333 |
| Gender_Legal_Sex | 183 | |||
| Female | — | — | ||
| Male | 0.84 | 0.62, 1.13 | 0.251 | |
| male | 183 | |||
| 0 | — | — | ||
| 1 | 0.84 | 0.62, 1.13 | 0.251 | |
| Race | 183 | |||
| Asian | — | — | ||
| Black | 0.47 | 0.15, 1.50 | 0.201 | |
| Other/Unknown | 0.44 | 0.14, 1.36 | 0.156 | |
| White | 0.54 | 0.20, 1.46 | 0.224 | |
| htn | 183 | |||
| 0 | — | — | ||
| 1 | 0.81 | 0.50, 1.29 | 0.372 | |
| cad | 183 | |||
| 0 | — | — | ||
| 1 | 1.15 | 0.85, 1.55 | 0.363 | |
| ace_arb | 183 | |||
| 0 | — | — | ||
| 1 | 1.03 | 0.71, 1.50 | 0.865 | |
| diu | 183 | |||
| 0 | — | — | ||
| 1 | 1.14 | 0.81, 1.60 | 0.459 | |
| ppi | 183 | |||
| 0 | — | — | ||
| 1 | 1.02 | 0.71, 1.46 | 0.912 | |
| steroids | 183 | |||
| 0 | — | — | ||
| 1 | 1.15 | 0.80, 1.67 | 0.456 | |
| smoking | 183 | |||
| 0 | — | — | ||
| 1 | 0.98 | 0.73, 1.33 | 0.919 | |
| ckd_stage_baseline_3 | 183 | |||
| stage 1 | — | — | ||
| stage 2 | 1.02 | 0.73, 1.43 | 0.896 | |
| stage 3 or more | 0.88 | 0.59, 1.31 | 0.526 | |
| ckd_stage_5year_3 | 183 | |||
| stage 1 | — | — | ||
| stage 2 | 1.02 | 0.71, 1.47 | 0.910 | |
| stage 3 or more | 0.95 | 0.63, 1.44 | 0.825 | |
| Bevacizumab | 183 | |||
| 0 | — | — | ||
| 1 | 1.07 | 0.53, 2.19 | 0.846 | |
| Cisplatin | 183 | |||
| 0 | — | — | ||
| 1 | 1.27 | 0.79, 2.04 | 0.328 | |
| Carboplatin | 183 | |||
| 0 | — | — | ||
| 1 | 1.21 | 0.88, 1.67 | 0.244 | |
| Pemetrexed | 183 | |||
| 0 | — | — | ||
| 1 | 0.97 | 0.62, 1.51 | 0.883 | |
| Gemcitabine | 183 | |||
| 0 | — | — | ||
| 1 | 1.58 | 0.98, 2.52 | 0.058 | |
| Cetuximab | 183 | |||
| 0 | — | — | ||
| 1 | 2.02 | 0.50, 8.24 | 0.325 | |
| Trastuzumab | 183 | |||
| 0 | — | — | ||
| 1 | 0.44 | 0.11, 1.79 | 0.249 | |
| VEGF_TKI | 183 | |||
| 0 | — | — | ||
| 1 | 1.47 | 0.91, 2.38 | 0.113 | |
| ICI_Class | 183 | |||
| PD1 | — | — | ||
| Combination | 1.35 | 0.77, 2.35 | 0.291 | |
| CTLA4 | 0.31 | 0.16, 0.63 | 0.001 | |
| PDL1 | 0.93 | 0.63, 1.39 | 0.734 | |
| cancer_type | 183 | |||
| Breast | — | — | ||
| Cutaneous / Melanoma | 0.32 | 0.11, 0.90 | 0.032 | |
| GI | 0.98 | 0.30, 3.27 | 0.978 | |
| GU | 0.61 | 0.21, 1.73 | 0.352 | |
| gyn | 1.75 | 0.19, 15.8 | 0.618 | |
| GYN | 0.85 | 0.24, 3.02 | 0.801 | |
| Head and Neck | 0.62 | 0.20, 1.91 | 0.402 | |
| Heme | 0.47 | 0.15, 1.45 | 0.190 | |
| Neuro | 0.44 | 0.08, 2.45 | 0.350 | |
| Sarcoma | 0.58 | 0.10, 3.16 | 0.525 | |
| thoracic | 3.41 | 0.37, 31.2 | 0.278 | |
| Thoracic | 0.51 | 0.18, 1.43 | 0.199 | |
| eGFR_CRE_baseline_decrease_10 | 183 | 1.01 | 0.94, 1.08 | 0.811 |
| pre_CRE_180days | 183 | 0.94 | 0.61, 1.45 | 0.782 |
| ckd_composite_5year | 183 | |||
| 0 | — | — | ||
| 1 | 0.94 | 0.69, 1.28 | 0.681 | |
| 1 HR = Hazard Ratio, CI = Confidence Interval | ||||